The biology and clinical relevance of the PTEN tumor suppressor pathway.
By I. Sansal, William R. Sellers. Journal of Clinical Oncology, 2004
971 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/91622b91bf6dd3b2cd530076cc1b65a50e613e02
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- J. Engelman
- Beth Levine
- Guido Kroemer
- Andrew J. Ewald
- Bert Vogelstein
- Morgan L. Truitt
- G. Peeters
- H. Askautrud
In Molecular Biology
- Guido Kroemer
- P. Pandolfi
- Beth Levine
- L. Galluzzi
- J. Engelman
- David M. Sabatini
- Eric H. Baehrecke
- Zena Werb
In Pathology and Forensic Medicine
Citations in the corpus
- The mTOR Signalling Pathway in Human Cancer (2012, background): “PTEN, the negative regulator of PI3K signalling, decreases its expression in many cancers, and may be downregulated through several mechanisms, including mutation, loss of heterozygosity, methylation, aberrant expression of regulatory microRNA, and protein instability [124,125].”
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism (2006, background): “cgi?id=153480">macrocephaly, multiple lipomas and haemangiomata ), which are two familial diseases characterized by benign tumours and high risk of cance”
- Perturbations of the AKT signaling pathway in human cancer (2005, background): “Somatic mutation and biallelic inactivation of PTEN occur frequently in high-grade glioblastoma, melanoma, and cancers of the prostate and endometrium (reviewed in Sansal and Sellers, 2004).”
- Ubiquitination regulates PTEN nuclear import and tumor suppression. (2007, background): “This finding further underscored the importance of a ‘‘non-Knudsonian’’ single-hit working model for loss of PTEN in tumor initiation and clarifies why indeed a majority of human tumors are retaining a wild-type (WT) copy of PTEN (Sansal and Sellers, 2004).”
- MicroRNA: Biogenesis, Function and Role in Cancer (2010, background): “Translational repression of PTEN by miR-21 leads to an accumulation of PIP3 that over stimulates the Akt pathway, activating multiple downstream pathways that stimulate cell growth and survival [275, 280, 285].”
- Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer (2009, neutral): “cgi?id=153480">Bannayan–Riley–Ruvalcaba's syndrome”
- Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. (2005, background): “ing, leading to increased activation of Akt (4, 5).”
- Mutant PIK3CA promotes cell growth and invasion of human cancer cells. (2005, background): “The tumor suppressor PTEN, which dephosphorylates PIP3 to PIP2, thus antagonizing PI3K activity, is deleted or mutated in several different tumor types (Li et al., 1997; Sansal and Sellers, 2004; Steck et al., 1997), and amplification of genomic regions containing AKT or PIK3CA genes has also been r”
- NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. (2007, positive): “The tumor suppressor PTEN plays critical roles in cell growth, migration, and death (Di Cristofano et al., 1998; Raftopoulou et al., 2004; Sansal and Sellers, 2004; Stambolic et al., 1998; Tamura et al., 1998).”
- Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy (2008, positive): “One of the most frequently mutated genes in human cancers is the gene encoding the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) protein (Sansal and Sellers, 2004; Stiles et al., 2004; Sulis and Parsons, 2003).”
- Autophagy in malignant transformation and cancer progression (2015, positive): “Moreover, the inactivation of PTEN as a result of sporadic mutations is very common among human cancers (Sansal & Sellers, 2004).”